The Drug Controller General of India, the drug regulator in India, has approved the use of favipirvir for the treatment of mild to moderate covid-19 patients. Pharmaceutical manufacturer Glenmark Pharmaceuticals said on Friday that it had received approval for the manufacture and marketing of the drug. The antiviral drug favipirvir (Fabiflu) will be used to treat mild to moderate covid-19 patients in the country.

In his statement, Glenmark said that the approval has been given on the basis of evaluation of data and consultation with the subject expert committee. Official sources said that the drug regulator has approved anti-viral drug favipirvir for emergency use. Following this approval, Glenmark Pharmaceuticals will make a separate application to state regulators to obtain a manufacturing license under the provisions of the Drugs and Cosmetics Act and its rules.

For your information, let us tell you that permission for this emergency use has been given with certain conditions. Which involves taking written consent from each patient or his / her representative. In addition, the company must first monitor 1,000 patients to assess safety and efficacy. The patient will be given a dose of 3,600 mg on the first day and then a 1,600 mg dose for a maximum of 14 days depending on the need. The same, DCGI recommended that the drug should be used only in adults. Liver and kidney patients, pregnant and lactating women, have been advised not to use it. Glenmark Pharmaceuticals was the first company in India to launch three clinical trials on Favipirvir for covid-19 patients.

Also Read: 

China-Nepal communist parties meeting amid dispute with India

China claims, 'Galwan Valley is ours, Indian Army crossed the border

US Secretary of State Mike Pompeo warns China over dispute with India

Vijay Mallya case: Supreme Court seeks clarification from its own registry